HHS Awards $196M for Pharmaceutical Prep Manufacturing to Emergent Manufacturing Operations
Contract Overview
Contract Amount: $196,434,000 ($196.4M)
Contractor: Emergent Manufacturing Operations Baltimore LLC
Awarding Agency: Department of Health and Human Services
Start Date: 2013-09-16
End Date: 2018-09-08
Contract Duration: 1,818 days
Daily Burn Rate: $108.0K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 5
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: IGF::OT::IGF
Plain-Language Summary
Department of Health and Human Services obligated $196.4 million to EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC for work described as: IGF::OT::IGF Key points: 1. Significant contract value for pharmaceutical preparation manufacturing. 2. Full and open competition was utilized, suggesting a competitive bidding process. 3. The contract spans nearly five years, indicating a long-term need. 4. Potential risks associated with manufacturing operations and supply chain reliability.
Value Assessment
Rating: fair
The contract value of $196.4 million over approximately five years suggests a substantial investment. Benchmarking against similar pharmaceutical manufacturing contracts would be necessary to fully assess pricing reasonableness.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, which typically fosters competitive pricing. The impact on price discovery is likely positive, as multiple bidders would have submitted proposals.
Taxpayer Impact: Taxpayer funds are being used for essential pharmaceutical preparation manufacturing, supporting public health preparedness. The competitive nature of the award aims to ensure value for money.
Public Impact
Supports national biodefense and public health emergency preparedness. Ensures availability of critical pharmaceutical products. Potential for job creation in the manufacturing sector.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Manufacturing process complexity
- Supply chain disruptions
- Dependence on a single awardee for critical supplies
Positive Signals
- Supports critical national security and health objectives
- Competitive award process
- Long-term commitment to a vital capability
Sector Analysis
This contract falls within the Healthcare sector, specifically pharmaceutical preparation manufacturing. Spending in this area is often driven by public health needs, national security, and emergency preparedness initiatives.
Small Business Impact
The data does not indicate whether small businesses were involved as subcontractors or prime contractors. Further analysis would be needed to determine small business participation.
Oversight & Accountability
The contract is managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS, an agency focused on public health emergencies. Oversight would likely involve monitoring manufacturing quality, delivery schedules, and compliance.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Health and Human Services Contracting
- Office of Assistant Secretary for Preparedness and Response Programs
Risk Flags
- Potential for cost overruns
- Manufacturing quality control issues
- Dependence on specific raw material suppliers
- Contract duration and potential for scope creep
- Ensuring long-term relevance of manufactured products
Tags
pharmaceutical-preparation-manufacturing, department-of-health-and-human-services, delivery-order, 100m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $196.4 million to EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC. IGF::OT::IGF
Who is the contractor on this award?
The obligated recipient is EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).
What is the total obligated amount?
The obligated amount is $196.4 million.
What is the period of performance?
Start: 2013-09-16. End: 2018-09-08.
What is the specific nature of the pharmaceutical preparations being manufactured and their criticality to public health emergencies?
The specific pharmaceutical preparations are not detailed in the provided data. However, given the awarding agency (ASPR), it is highly probable that these preparations are critical medical countermeasures intended for use during public health emergencies, such as biodefense threats or pandemics. Their criticality lies in their role in saving lives and mitigating the impact of widespread health crises.
What are the key performance indicators (KPIs) and quality control measures in place for this manufacturing contract?
Key performance indicators would likely include adherence to strict manufacturing timelines, product quality and purity standards (e.g., FDA regulations), and successful delivery of finished goods. Quality control measures would involve rigorous testing, validation of manufacturing processes, and regular audits of the contractor's facilities and operations to ensure compliance and product efficacy.
How does this contract contribute to the overall resilience of the nation's pharmaceutical supply chain?
This contract contributes to supply chain resilience by ensuring a domestic manufacturing capability for critical pharmaceutical products. By securing production capacity through a long-term contract, the government reduces reliance on foreign sources and mitigates risks associated with global supply chain disruptions, thereby enhancing the nation's ability to respond to health emergencies.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Solicitation ID: 12100SOL00026
Offers Received: 5
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 5901 E LOMBARD ST, BALTIMORE, MD, 21224
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations
Financial Breakdown
Contract Ceiling: $196,434,000
Exercised Options: $196,434,000
Current Obligation: $196,434,000
Contract Characteristics
Multi-Year Contract: Yes
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: HHSO100201300008I
IDV Type: IDC
Timeline
Start Date: 2013-09-16
Current End Date: 2018-09-08
Potential End Date: 2018-09-08 00:00:00
Last Modified: 2024-07-06
More Contracts from Emergent Manufacturing Operations Baltimore LLC
- Emergent Ciadm Manufacturing Capacity Reservation and Expansion — $470.9M (Department of Health and Human Services)
- Federal Contract — $105.0M (Department of Health and Human Services)
View all Emergent Manufacturing Operations Baltimore LLC federal contracts →
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →